Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Human inhaled insulin powder (HIIP ... clinical trial with Technosphere insulin and received lecturing fees from Pfizer Inc. and NovoNordisk. The author has no other relevant affiliations or ...

“The availability of insulin to be inhaled through the lungs will provide a new and innovative option for patients with diabetes mellitus,” he added. Afrezza has been evaluated in over 70 ...

Mumbai, Dec 11 Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on ...

The availability of insulin to be inhaled through the lungs will provide a new and innovative option for patients with diabetes mellitus,” Dr. Jaideep Gogtay, Global Chief Medical Officer ...

MUMBAI:Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on Wednesday. The ...

Mumbai, Dec 11 (IANS): Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said ...

“We are excited for Cipla to market the first inhaled insulin treatment option for adults living with diabetes in India and expect to prepare product for export by the end of 2025.” MannKind ...